The global Keytruda Market was valued at USD 31.4 billion in 2025 and is projected to grow from USD 32.7 billion in 2026 to USD 25.0 billion by 2033, registering a CAGR of -3.8% from 2026 to 2033. While Keytruda (pembrolizumab) remains one of the most successful immunotherapy drugs globally, the market is expected to face headwinds over the forecast period due to patent expiration,...

According to a newly published market research report by 24LifeSciences, global advanced renal cell carcinoma therapeutics market was valued at USD 3.2 billion in 2023 and is projected to reach USD 5.8 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.3% during the forecast period 20242030. Advanced renal cell carcinoma therapeutics encompass targeted therapies,...

According to a newly published market research report by 24LifeSciences, global PD-1 and PD-L1 monoclonal antibody market was valued at USD 32.6 billion in 2025 and is projected to reach USD 63.4 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.7% during the forecast period 2026–2034. PD-1/PD-L1 monoclonal antibodies represent a groundbreaking class of...

According to a new report from Intel Market Research, the global Pembrolizumab market was valued at USD 21.8 billion in 2025 and is projected to grow from USD 24.3 billion in 2026 to USD 42.7 billion by 2034, exhibiting a robust CAGR of 7.3% during the forecast period. This growth is driven by increasing cancer prevalence, rising immunotherapy adoption, expanding regulatory approvals for new...

According to a newly published market research report by 24LifeSciences, global immune checkpoint inhibitors market was valued at USD 42.6 billion in 2023 and is projected to reach USD 98.7 billion by 2032, growing at a compound annual growth rate (CAGR) of 10.7% during the forecast period 2025-2032. Immune checkpoint inhibitors are monoclonal antibodies that block proteins used by cancer cells...